Enanta Pharmaceuticals
ENTA
107 hedge funds and large institutions have $114M invested in Enanta Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 35 increasing their positions, 31 reducing their positions, and 27 closing their positions.
13% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 31
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 111 → 107 (-4)
6.24% less ownership
Funds ownership: 100.19% → 93.95% (-6.2%)
15% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 27
21% less call options, than puts
Call options by funds: $56K | Put options by funds: $71K
48% less capital invested
Capital invested by funds: $220M → $114M (-$105M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$9.95M |
| 2 |
KAM
Krensavage Asset Management
New York
|
+$5.94M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$3.18M |
| 4 |
Millennium Management
New York
|
+$1.59M |
| 5 |
BlackRock
New York
|
+$1.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$10.4M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$8.14M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$6.73M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$4.93M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.47M |
ENTA Hedge Fund Activity: Q4 2024 in Review
107 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q4 2024, worth a combined $114M — down 48% from $220M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of ENTA and 23 opened new positions — a net loss of 4 holders — while 31 trimmed existing stakes and 35 added.
The largest buyer was RA Capital Management, opening a new position worth an estimated $9.95M. The largest seller was Armistice Capital, exiting entirely with an estimated $10.4M sold.
- 107 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q4 2024, down from 111 in Q3 2024.
- Funds reported $114M of Enanta Pharmaceuticals stock for Q4 2024, down 48% quarter-over-quarter.
- 23 funds opened new Enanta Pharmaceuticals positions in Q4 2024 and 27 closed out, a net change of -4 holders.
- The largest Enanta Pharmaceuticals buyer in Q4 2024 was RA Capital Management, an estimated $9.95M added.
- The largest Enanta Pharmaceuticals seller in Q4 2024 was Armistice Capital, an estimated $10.4M sold.
Based on aggregated 13F filings for Q4 2024.